Lab Results:
janoshik.com/tests/44396-S5_VYY2576XF7LQ
Semaglutide is a synthetic GLP‑1 receptor agonist peptide engineered for research use only (RUO). It is widely studied for its role in glucose regulation, appetite signaling, and energy balance, with a unique molecular design that extends its half‑life to about 7 days, making it a cornerstone compound in metabolic and cardiovascular research.
🧬 Product Description (Research Use Only)
What Semaglutide Is
- Synthetic analog of human GLP‑1 (Glucagon‑Like Peptide‑1), approximately 94% identical to the native hormone.
- Modified with:
- Aib substitution at position 8 → resistance to DPP‑4 enzymatic degradation.
- Arg substitution at position 34 → improved receptor interaction geometry.
- C18 fatty diacid chain at Lys26 → enables albumin binding, dramatically extending half‑life (~165 hours).
- These modifications allow once‑weekly dosing in research models, compared to native GLP‑1’s 1–2 minute half‑life.
Mechanism of Action in Research
- Pancreatic Beta Cells: Stimulates glucose‑dependent insulin secretion via cAMP/PKA signaling cascades.
- Alpha Cells: Suppresses glucagon release, improving glycemic control.
- Hypothalamus & Brainstem: Engages appetite‑regulating circuits (POMC/CART activation, NPY/AgRP inhibition), reducing food intake.
- Gastrointestinal System: Slows gastric emptying, enhancing satiety and lowering postprandial glucose.
- Cardiovascular & Inflammatory Pathways: Preclinical studies show reduced atherosclerotic plaque formation and downregulation of inflammatory markers.
Research Applications
- Type 2 Diabetes: Extensive evidence from the SUSTAIN trial program.
- Obesity & Weight Management: STEP trials demonstrated significant weight reduction.
- Cardiovascular Outcomes: SELECT trial showed reduced major adverse cardiovascular events.
- Kidney & Liver Research: FLOW trial (renal outcomes) and NAFLD studies highlight broader metabolic utility.
- Neuroendocrine Studies: Investigations into hypothalamic signaling and appetite regulation.
Laboratory Standards
- Purity: ≥99% verified by HPLC.
- Molecular Weight Confirmation: Required via COA (Certificate of Analysis).
- Validated Concentrations: Research protocols typically start at 0.25 mg/week, escalating to 0.5–1.0 mg, with upper ranges of 1.7–2.4 mg documented in metabolic studies.
⚠️ Compliance Notes
- For Research Use Only (RUO): Not approved for human or veterinary consumption.
- Investigational Status: FDA‑approved under brand names Ozempic, Wegovy, and Rybelsus for clinical use, but peptides sold here are strictly for laboratory research.
- Experimental Integrity: Use only validated concentrations to ensure reproducibility and comparability with published data.
Reviews
There are no reviews yet.